Treos Bio
Phase 1Treos Bio is a clinical stage company developing next generation of effective off-the-shelf peptide active cancer immunotherapies based on a novel perspective on how HLA genes influence immune responses to cancer.
Founded
2015
Focus
Vaccines
About
Treos Bio is a clinical stage company developing next generation of effective off-the-shelf peptide active cancer immunotherapies based on a novel perspective on how HLA genes influence immune responses to cancer.
Funding History
1Total raised: $10M
Series A$10MMorningside VenturesMar 15, 2020
Company Info
TypePrivate
Founded2015
LocationLondon, United Kingdom
StagePhase 1
Contact
SIMILAR COMPANIES
Abbexa
Pre-clinical · Cambridge
Accentus Medical
Pre-clinical · Oxford
AbOliGo
Pre-clinical · London
Bigespas
Pre-clinical · London
Actimed Therapeutics
Pre-clinical · London
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile